The survey finding is real. So is the fact that it was commissioned by an organisation that advocates plant-based diets — and the underlying evidence is genuinely mixed.
Menstrual changes, chills, hot flashes. Nobody asked these patients — which is exactly why the answers are interesting, and why they prove nothing.
Crohn’s patients ate the same plant foods as healthy controls and had more oxalate in their stool. The difference was in the transporters, not the diet.
Approved two months early, one week after GSK closed the $10.6 billion deal that bought it. The target drives 2% of lung cancers.
The allegation is comparing top doses against original lower ones. Whether that is misleading depends on what a fair comparison would even look like.
Not an official shortage, and patients cannot find it. The gap between those two statements is where insulin supply problems live.
Same molecule, different delivery. Coffee gives 9–21 mg per ounce; an energy shot gives 40–69 — and concentration is the whole argument.
An algorithm read 20,000 genes looking for hormones nobody had noticed. It found a 12-amino-acid peptide the human body already makes.
Tirzepatide showed the strongest signal and produces the most weight loss. That correlation is the most likely explanation, and it is not reassuring or alarming — it is specific.
Decaf worked about as well as regular. That single detail rules out caffeine as the explanation and points somewhere else entirely.
Nine vaccinated people caught the wrong Ebola species and all nine survived. Not proof — but an argument that the question should be tested rather than debated.
Hunger and craving are different circuits. These drugs appear to act on both — in mice engineered with human receptors, which is the necessary caveat.